Zeo ScientifiX, Inc. (ZEOX) Stock Price & Analysis
Zeo ScientifiX, Inc. (ZEOX) — price $1.25 (+4.17%), as of the Oct 2, 2026 trading session; market cap $9.80M.
Educational signal · not a buy or sell recommendation · How to read this
Zeo ScientifiX, Inc. · ZEOX
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company focused on developing biological therapeutics for degenerative diseases. Its lead product, Zofin, targets multiple conditions and is currently in clinical trials.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.25 | |
| Change on the day | +4.17% | |
| 52-week range | $0.97 – $2.99 | |
| Market capitalisation | $9.80M | |
| Shares traded on the day | 800 |
Price & events
Other perspectives
Council score for Zeo ScientifiX (ZEOX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
2 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the ZEOX film — every key number, told as a short cinematic story
~2 min · open the film
What is Zeo ScientifiX (ZEOX), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Zeo ScientifiX, Inc. (ZEOX) is the company analyzed here. It employs 20 people and is led by Ian T. Bothwell. In Q2 FY2026 it reported revenue of $3M and net income of -$145,000. The market values it at $9.80M.
What do the latest results show for Zeo ScientifiX (ZEOX)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $3M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $3M | -$145,000 | -$0.02 (diluted) |
| Q1 FY2026 | $1M | -$852,000 | -$0.12 (diluted) |
| Q4 FY2025 | $2M | -$815,000 | -$0.13 (diluted) |
| Q3 FY2025 | $1M | -$2M | -$0.32 (diluted) |
What are the financial strengths and risks for Zeo ScientifiX (ZEOX)?
Short answer
The distress and quality screens read Altman Z -24.30 · Piotroski F 5. Trailing ratios: ROE 455.9% · ROA -99.9% · current ratio 1.05 · earnings yield -40.1% · free-cash-flow yield -13.8%.
The records behind this page
Insider activity
Form 4 records via FMP · Available records within the last 180 days, newest dated Jun 10, 2026 (coverage not recorded)
- Transactions
- 4
- Identified insiders
- 4
- Purchases
- 0
- Sales
- 0
- Other transactions
- 4
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Investor Questions: ZEOX Stock
These answers are editorial: 1 of these 8 answers is drawn from the ZEOX research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is ZEOX a good stock to buy?
Stock Expert AI does not rate ZEOX buy, sell or hold. Zeo ScientifiX, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ZEOX stock price today?
The last price recorded on this page for Zeo ScientifiX, Inc. (ZEOX) is $1.25, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
How does Zeo ScientifiX, Inc. navigate regulatory approval processes?
Zeo ScientifiX, Inc. follows a structured approach to navigate regulatory approval processes, focusing on compliance with FDA guidelines for clinical trials.
What are the key factors to evaluate for ZEOX?
Evaluate ZEOX on fundamentals, analyst consensus, and risk factors. No dividend yield reflects the company's focus on reinvestment for growth. Not financial advice.
How frequently does ZEOX data refresh on this page?
ZEOX's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ZEOX's recent stock price performance?
Zeo ScientifiX, Inc. (ZEOX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product pipeline with potential for high market demand. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZEOX overvalued or undervalued right now?
Zeo ScientifiX, Inc. (ZEOX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ZEOX before investing?
Before investing in Zeo ScientifiX, Inc. (ZEOX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (14 figures)
The 14 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 9 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $1.25 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T21:24:43.027Z. | |
px.change | Change on the day | +4.17% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $9.80M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T21:24:42.041Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.05 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 800 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $3M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | -$145,000 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.insiders | Insider transactions via FMP | 4 transactions · 0 purchases, 0 sales, 4 other transactions · 4 identified insiders · available records within the last 180 days, newest dated Jun 10, 2026 (coverage not recorded) | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 5 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $0.97 – $2.99 | UNRECORDED | Stored company-profile observation — Captured 2026-10-05 | |
id.employees | Employees | 20 | UNRECORDED | Stored company-profile observation — Captured 2026-10-05 | |
id.ceo | Chief executive | Ian T. Bothwell | UNRECORDED | Stored company-profile observation — Captured 2026-10-05 | |
fin.scores | Distress and quality screens | Altman Z -24.30 · Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 455.9% · ROA -99.9% · current ratio 1.05 · earnings yield -40.1% · free-cash-flow yield -13.8% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.